Home›Trial›NCT04580420
NCT04580420Phase 2RECRUITING

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

Study Summary

The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

Conditions
Primary Hyperoxaluria Type 1End Stage Renal Disease
Interventions / Drugs
DCR-PHXC
View on ClinicalTrials.gov ↗
Sponsor
NVO
Novo Nordisk
Diabetes/Obesity
F12/100
Study Details
Enrollment28 participants
Primary Completion—
Lead SponsorDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Data Retrieved2026-04-11 02:55:47.366893+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 28 participants
Sponsor Catalyst Profile

Novo Nordisk (NVO) is the sponsoring company for this trial. BiotechSign currently grades this company F (12/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NVO Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.